Friday, September 22, 2023
Courthouse News Service
Friday, September 22, 2023 | Back issues
Courthouse News Service Courthouse News Service

$9 Billion Merger

Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders claim in a federal class action.

SEATTLE — Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders claim in a federal class action.

Categories / Securities

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...